vorapaxar + antiplatelet therapy + standard medical therapy

This treatment regimen consists of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar added to background antiplatelet therapy (APT), typically aspirin, and standard medical therapy (SMT) for the management of peripheral artery disease (PAD) and intermittent claudication. Vorapaxar is a small molecule drug that inhibits thrombin-induced platelet aggregation by targeting the PAR-1 receptor on platelets. This specific combination was evaluated in the Phase 4 XLPAD-TRACE trial (Excellence in Peripheral Artery Disease Thrombin Receptor Antagonist Intervention in Claudication Evaluation), sponsored by the North Texas Veterans Healthcare System. The trial aimed to determine if the addition of vorapaxar 2.08 mg daily could improve peak walking time in patients with established PAD and claudication. Results from the study indicated that the addition of vorapaxar did not significantly improve walking performance or quality of life measures in this patient population compared to placebo plus background APT and SMT.

Brand names

Zontivity

Other names

Vorapaxar + APT + SMTXLPAD-TRACE regimen